The firm’s psoriasis cream was found safe and more effective than placebos in Phase II trials.
Meytag Technology Incubator portfolio company DermiPsor Ltd. will begin Phase III clinical trials of its psoriasis cream after it was found to be safe and more effective than placebos in Phase II trials.
The Phase II trial included 168 patients at five medical centers in the US. All patients were treated with DermiPsor’s psoriasis cream on one side of their bodies and with a placebo on the other in order to conduct a comparative study. Neither the patients nor their doctors knew which cream was applied on which side.
DermiPsor’s psoriasis cream was found to be safe in all four combinations of active pharmaceutical ingredient (API) mixes. The cream was also found to be more effective than both the placebo and each of the APIs taken separately. The trial identified the most effective blend of APIs.
Meytag, based is Katzrin, is a subsidiary of Capital Point Ltd. (TASE:CPTP).
Published by Globes [online], Israel business news - www.globes.co.il - on October 16, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007